• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于人群的BRCA2基因突变携带者患乳腺癌风险的研究。

Population-based study of risk of breast cancer in carriers of BRCA2 mutation.

作者信息

Thorlacius S, Struewing J P, Hartge P, Olafsdottir G H, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjörd J E

机构信息

Molecular and Cell Biology Research Laboratory, Icelandic Cancer Society, Reykjavik.

出版信息

Lancet. 1998 Oct 24;352(9137):1337-9. doi: 10.1016/s0140-6736(98)03300-5.

DOI:10.1016/s0140-6736(98)03300-5
PMID:9802270
Abstract

BACKGROUND

Estimates of an 80-90% risk of breast cancer for carriers of germline mutations in the BRCA1 and BRCA2 genes are based on studies of families at high risk of breast cancer. Risk estimates for a population are possible if the mutation status of a representative sample of that population can be assessed. In Iceland, one common founder BRCA2 mutation occurs in 0.6% of the population. Iceland has a population-based cancer registry and a large collection of pedigrees, and estimation of cancer risk in mutation carriers is therefore possible.

METHODS

We studied 575 breast-cancer patients, 541 women and 34 men unselected for family history of breast cancer. Data on cancer in first-degree relatives were available from the cancer registry. Risk of cancer was estimated by comparing the history of cancer in first-degree relatives of carriers and non-carriers.

FINDINGS

56 (10.4%) of the 541 women and 13 (38%) of the 34 men carried the 999del5 mutation. The estimated risk of breast cancer at age 50 for all female carriers of the 999del5 mutation was 17.0% (95% CI 9.1-25.9) and 37.2% (22.4-53.9) at age 70.

INTERPRETATION

The results of our population-based study show that the mean risk of breast cancer in carriers of mutation in BRCA2 is lower than previously suggested. Individual risk assessment will, however, have to take account of family history.

摘要

背景

BRCA1和BRCA2基因种系突变携带者患乳腺癌的风险估计为80% - 90%,这是基于对乳腺癌高危家族的研究得出的。如果能够评估该人群代表性样本的突变状态,就有可能对人群的风险进行估计。在冰岛,一种常见的始祖BRCA2突变存在于0.6%的人群中。冰岛有基于人群的癌症登记处和大量的家系收集,因此有可能估计突变携带者的癌症风险。

方法

我们研究了575例乳腺癌患者,541名女性和34名男性,这些患者未根据乳腺癌家族史进行选择。一级亲属的癌症数据可从癌症登记处获得。通过比较携带者和非携带者一级亲属的癌症病史来估计癌症风险。

研究结果

541名女性中有56名(10.4%)和34名男性中有13名(38%)携带999del5突变。所有999del5突变女性携带者在50岁时患乳腺癌的估计风险为17.0%(95%置信区间9.1 - 25.9),在70岁时为37.2%(22.4 - 53.9)。

解读

我们基于人群的研究结果表明,BRCA2突变携带者患乳腺癌的平均风险低于先前的推测。然而,个体风险评估必须考虑家族史。

相似文献

1
Population-based study of risk of breast cancer in carriers of BRCA2 mutation.基于人群的BRCA2基因突变携带者患乳腺癌风险的研究。
Lancet. 1998 Oct 24;352(9137):1337-9. doi: 10.1016/s0140-6736(98)03300-5.
2
Study of a single BRCA2 mutation with high carrier frequency in a small population.对一个小群体中具有高携带频率的单一BRCA2突变的研究。
Am J Hum Genet. 1997 May;60(5):1079-84.
3
Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.1920 - 2000年冰岛BRCA2基因突变携带者乳腺癌风险变化的基于人群的研究。
J Natl Cancer Inst. 2006 Jan 18;98(2):116-22. doi: 10.1093/jnci/djj012.
4
A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.对姐妹对肿瘤中乳腺癌基因位点的突变和杂合性缺失进行的一项群体研究:在冰岛,两个反复出现的突变似乎可解释所有与BRCA1/BRCA2相关的乳腺癌病例。
J Med Genet. 1998 Jun;35(6):446-9. doi: 10.1136/jmg.35.6.446.
5
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.丹麦年轻女性多灶性或双侧乳腺癌患者的BRCA1和BRCA2突变状态及癌症家族史。
J Med Genet. 2001 Jun;38(6):361-8. doi: 10.1136/jmg.38.6.361.
6
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.基于人群的BRCA1和BRCA2中一组特定蛋白质截短突变的乳腺癌平均年龄特异性累积风险估计。澳大利亚乳腺癌家族研究。
Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):741-7.
7
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.预防乳腺癌的未来可能性:BRCA1和BRCA2突变携带者的干预策略。
Breast Cancer Res. 2000;2(4):283-90. doi: 10.1186/bcr70. Epub 2000 May 25.
8
A low proportion of BRCA2 mutations in Finnish breast cancer families.芬兰乳腺癌家族中BRCA2突变的比例较低。
Am J Hum Genet. 1997 May;60(5):1050-8.
9
BRCA2 mutation in Icelandic prostate cancer patients.冰岛前列腺癌患者中的BRCA2基因突变
J Mol Med (Berl). 1997 Oct;75(10):758-61. doi: 10.1007/s001090050162.
10
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.冰岛具有不同癌症表型的男性和女性乳腺癌家族中的单个BRCA2突变。
Nat Genet. 1996 May;13(1):117-9. doi: 10.1038/ng0596-117.

引用本文的文献

1
Genetic Testing for Successful Cancer Treatment.用于癌症成功治疗的基因检测
Cureus. 2023 Dec 4;15(12):e49889. doi: 10.7759/cureus.49889. eCollection 2023 Dec.
2
Circulating and extracellular vesicle-derived microRNAs as biomarkers in bone-related diseases.循环和细胞外囊泡衍生的 microRNAs 作为与骨相关疾病的生物标志物。
Front Endocrinol (Lausanne). 2023 May 24;14:1168898. doi: 10.3389/fendo.2023.1168898. eCollection 2023.
3
Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin.
NRF2在乳腺癌中的作用及多酚和褪黑素的潜在治疗作用
Molecules. 2021 Mar 25;26(7):1853. doi: 10.3390/molecules26071853.
4
A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel.伊朗 BRCA1/2 基因致病性变异的综合参考资料:已发表、未发表和新发现的。
Fam Cancer. 2022 Apr;21(2):137-142. doi: 10.1007/s10689-021-00242-4. Epub 2021 Mar 23.
5
Biomarkers in acute graft--host disease: new insights.急性移植物抗宿主病中的生物标志物:新见解
Ther Adv Hematol. 2019 Dec 4;10:2040620719891358. doi: 10.1177/2040620719891358. eCollection 2019.
6
Somatic variants of potential clinical significance in the tumors of phenocopies.拟表型肿瘤中具有潜在临床意义的体细胞变异。
Hered Cancer Clin Pract. 2019 Jul 16;17:21. doi: 10.1186/s13053-019-0117-5. eCollection 2019.
7
Favorable Long-Term Outcome in Male Breast Cancer.男性乳腺癌的长期预后良好。
Eur J Breast Health. 2018 Jul 1;14(3):180-185. doi: 10.5152/ejbh.2018.3946. eCollection 2018 Jul.
8
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?嵌合体能否解释 BRCA 阳性家族中 BRCA 阴性的乳腺癌/卵巢癌?
PLoS One. 2018 Apr 16;13(4):e0195497. doi: 10.1371/journal.pone.0195497. eCollection 2018.
9
Gynecologic cancer mortality in Trinidad and Tobago and comparisons of mortality-to-incidence rate ratios across global regions.特立尼达和多巴哥的妇科癌症死亡率以及全球各地区死亡率与发病率比率的比较。
Cancer Causes Control. 2017 Nov;28(11):1251-1263. doi: 10.1007/s10552-017-0961-4. Epub 2017 Sep 15.
10
BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.BRCA突变与乳腺癌生存:一项更新的系统评价和荟萃分析。
Oncotarget. 2016 Oct 25;7(43):70113-70127. doi: 10.18632/oncotarget.12158.